Tyler Izatt
Overview
Explore the profile of Tyler Izatt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
872
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saulnier Sholler G, Bergendahl G, Lewis E, Kraveka J, Ferguson W, Nagulapally A, et al.
Genome Med
. 2024 Feb;
16(1):28.
PMID: 38347552
Background: Children with relapsed central nervous system (CNS tumors), neuroblastoma, sarcomas, and other rare solid tumors face poor outcomes. This prospective clinical trial examined the feasibility of combining genomic and...
2.
Sakthikumar S, Warrier M, Whitley D, Facista S, Adkins J, Aman S, et al.
Vet Comp Oncol
. 2023 Dec;
22(1):30-41.
PMID: 38053317
A genomic understanding of the oncogenic processes and individual variability of human cancer has steadily fueled improvement in patient outcomes over the past 20 years. Mutations within tumour tissues are...
3.
Byron S, Hendricks W, Nagulapally A, Kraveka J, Ferguson W, Brown V, et al.
Cancer Res
. 2021 Oct;
81(23):5818-5832.
PMID: 34610968
Children with treatment-refractory or relapsed (R/R) tumors face poor prognoses. As the genomic underpinnings driving R/R disease are not well defined, we describe here the genomic and transcriptomic landscapes of...
4.
LoRusso P, Sekulic A, Sosman J, Liang W, Carpten J, Craig D, et al.
PLoS One
. 2021 Apr;
16(4):e0248097.
PMID: 33826614
Although combination BRAF and MEK inhibitors are highly effective for the 40-50% of cutaneous metastatic melanomas harboring BRAFV600 mutations, targeted agents have been ineffective for BRAFV600wild-type (wt) metastatic melanomas. The...
5.
Dizman N, Lyou Y, Salgia N, Bergerot P, Hsu J, Enriquez D, et al.
J Immunother Cancer
. 2020 Jul;
8(2).
PMID: 32661119
Background: The clinical significance of tumor-specific genomic alterations in metastatic renal cell carcinoma (mRCC) is emerging, with several studies suggesting an association between mutations and response with immunotherapy (IO). We...
6.
Balak C, Belnap N, Ramsey K, Joss S, Devriendt K, Naymik M, et al.
Am J Med Genet A
. 2018 Aug;
176(7):1549-1558.
PMID: 30160831
Chromosome 1q41-q42 deletions have recently been associated with a recognizable neurodevelopmental syndrome of early childhood (OMIM 612530). Within this group, a predominant phenotype of developmental delay (DD), intellectual disability (ID),...
7.
Bryce A, Borad M, Egan J, Condjella R, Liang W, Fonseca R, et al.
Clin Genitourin Cancer
. 2017 Jan;
15(4):e727-e734.
PMID: 28057415
No abstract available.
8.
Borad M, Egan J, Condjella R, Liang W, Fonseca R, Ritacca N, et al.
Sci Rep
. 2016 Dec;
6(1):25.
PMID: 28003660
DNA focused panel sequencing has been rapidly adopted to assess therapeutic targets in advanced/refractory cancer. Integrated Genomic Profiling (IGP) utilising DNA/RNA with tumour/normal comparisons in a Clinical Laboratory Improvement Amendments...
9.
Sekulic A, Liang W, Tembe W, Izatt T, Kruglyak S, Kiefer J, et al.
Mol Genet Genomic Med
. 2015 Mar;
3(2):130-6.
PMID: 25802883
Matching molecularly targeted therapies with cancer subtype-specific gene mutations is revolutionizing oncology care. However, for rare cancers this approach is problematic due to the often poor understanding of the disease's...
10.
Nasser S, Kurdolgu A, Izatt T, Aldrich J, Russell M, Christoforides A, et al.
Pac Symp Biocomput
. 2015 Jan;
:56-67.
PMID: 25592568
The ability to rapidly sequence the tumor and germline DNA of an individual holds the eventual promise of revolutionizing our ability to match targeted therapies to tumors harboring the associated...